Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Health Ministry to...

    Health Ministry to bring all Medical Devices under CDSCO regulations, Invites comments

    Farhat NasimWritten by Farhat Nasim Published On 2019-10-19T17:38:30+05:30  |  Updated On 16 Aug 2021 5:40 PM IST

    Once finalized, the medical device makers will have to get licences from the Drug Controller General of India (DCGI) while CDSCO will be the nodal authority to investigate the quality, safety-related failure, complaints and can suspend the registration based on the outcome of the investigation.


    New Delhi: Through a recent notification, the Union Health Ministry has proposed to bring all medical devices including contraceptives and implants under the regulatory framework of the apex drug regulatory body, Central Drugs and Standard Control Organisation (CDSCO), mandating all medical devices to get CDSCO certification.


    In this regard, the government has sought comments from all stakeholders within 30 days before the draft notification is finalized, in the draft notification the timeline for implementation is December 1. The suggestions/comments/objections may be forwarded within 30 days from the date of issue of this Notice by email at drugsdiv-mohfw@,gov.in or by post to Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Room No. 4I4A, D Wing, Nirman Bhawan, New Delhi

    Only the suggestions/comments/objections received on the above email/address within the period of 30 days shall be taken into consideration for finalization of the notification, the notification added

    The proposal is under pursuance of sub-section (b) of section 3 of the Drugs and Cosmetics Act, 1940 to regulate them as per the provisions of Medical devices Act and Medical Devices Rules, 2017 framed thereunder.


    Sub-section (b) of section 3 of the Drugs and Cosmetics Act, 1940 talks about all substances considered as "DRUGS".


    Medical Dialogues had earlier reported, in a significant move to provide safety to patients and regulate the quality of diagnostic and medical devices in India, the health ministry had notified eight medical equipment, including all implantable devices, as "drugs" under Section 3 of the Drugs and Cosmetics Act, effective from April 1, 2020.


    Also Read: Eight medical devices including CT, MRI, X-ray notified as DRUGS by health ministry


    The recent draft notification dated October 18, 2019, stated;


    In pursuance of sub-clause (iv) of clause (b) of section 3 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board, hereby specifies the following devices intended for use in human beings or animals as drugs with effect from the 1st day of December, 2019,namely:-


    All devices including an instrument, apparatus, appliance, implant, material or other article; whether used alone or in combination, including a software or an accessory, intended by its manufacturer to be used specially for human beings or animals which does not achieve the primary intended action in or on human body or animals by any pharmacological or immunological or metabolic means, but which may assist in its intended function by such means for one or more of the specific purposes of -




    • diagnosis, prevention, monitoring, treatment or alleviation of any disease or disorder;

    • diagnosis, monitoring, treatment, alleviation or assistance for, any injury or disability;

    • investigation, replacement or modification or support of the anatomy or of a physiological process;

    • supporting or sustaining life;

    • disinfection of medical devices; and

    • control of conception.


    In this regard, the government has sought comments from all stakeholders within 30 days before the draft notification is finalized, in the draft notification the timeline for implementation is December 1.


    Once finalized, the medical device makers will have to get licences from the Drug Controller General of India (DCGI) while CDSCO will be the nodal authority to investigate the quality, safety-related failure, complaints and can suspend the registration based on the outcome of the investigation.


    The move will help enforce standards to ensure the safety and effectiveness of these products while its pricing regulator, the National Pharmaceutical Pricing Authority (NPPA) will monitor the prices.


    Also Read: PIL against Health Ministry notifying 8 medical devices as DRUGS, Delhi HC seeks Centre reply

    CDSCOcontraceptivesDrugs Technical Advisory BoardDTABgovt of indiaHealth Ministryimplantsmedical deviceMedical DevicesMedical Devices ActMedical Devices RulesNational Pharmaceutical Pricing AuthorityNPPA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok